摘要
本研究探讨骨髓增生异常综合症(MDS)患者中细胞周期蛋白A1(cyclin A1)mRNA表达及其临床意义。采用逆转录聚合酶链反应(RT-PCR)法检测56例骨髓增生异常综合症患者及10例正常人骨髓细胞中的cyclin A1表达及cdk2、p21cip1的mRNA表达。结果表明:MDS患者中cyclin A1的阳性率及mRNA表达水平(69.64%;0.964±1.879)均较正常人(0%;0.012±0.014)明显增高(p<0.01);在初治MDS患者中,MDS-RAEB组cyclinA1表达水平(1.895±1.769)明显高于MDS-RA组(0.629±1.583)(p<0.01);治疗后MDS患者的cyclin A1表达水平较治疗前明显降低(p<0.01)。结论:MDS患者cyclin A1表达水平较正常人明显增高,其异常表达可能是影响MDS患者预后的指标之一。
The purpose of this study was to evaluate the expression of cyclin A1 mRNA in patients with myelodysplastic syndrome （MDS） and its clinical significance. The expression of cyclin A1, cdk2 and p21 cip~ mRNA in the bone marrow from 56 patients with MDS and 10 normal control were measured by using reverse transcription polymerase chain reaction （RT-PCR） technique. The results indicated that the positive rate and the expression level of cyclin A1 in MDS patients （69.64% ; 0. 964 ± 1. 879） were significantly higher than those in nromal control （0% ; 0.012 ±0.014） （p 〈 0.01 ） . Among de-novo MDS patients, the expression level of cyclin A1 mRNA in the MDS- RAEB group （ 1. 895 ± 1. 769） was higher than that in MDS-RA group（0.629 ± 1. 583 ） （p 〈 0.01 ）. The expression level of cyclin A1 mRNA in post-treatment group was significantly lower than that in prior-treatment group （p 〈 0.01 ）. It is concluded that the mRNA expression of cyclin A1 in MDS patients is higher than that in normal control, the abnormal expression of cyclin A1 may be used as a prognostic marker in MDS patients.
出处
《中国实验血液学杂志》
CAS
CSCD
2009年第2期377-381,共5页
Journal of Experimental Hematology
